Recent research have converged on the intersection of GLP-1|glucose-dependent insulinotropic polypeptide|GCGR stimulant therapies and DA communication. While GIP agonists are increasingly employed for addressing type 2 T2DM, their potential effects on motivation circuits, specifically mediated by